, Volume 69, Issue 1–2, pp 85–89 | Cite as

Enantiomeric Separation of Moxifloxacin and Its (R,R)-Isomer by Ligand-Exchange Chiral Chromatography

  • M. Ravikumar
  • M. Satish Varma
  • T. Satyanarayana Raju
  • P. Suchitra
  • P. Yadagiri Swamy
Full Short Communication


A new stereospecific LC method for the separation and quantification of moxifloxacin and its (R,R)-enantiomer in bulk drug was developed and validated by ligand-exchange liquid chromatography on a reversed phase column using aqueous mobile phase containing the chiral reagent l-isoleucine-Cu(II). The UV detector was operated at 293 nm. The flow rate of mobile phase was set at 0.9 mL min−1. The achiral ODS column offers good separation of the two enantiomers in less than 20 min. The test concentration was 1,000 μg mL−1 in the mobile phase. This method was capable of detecting the (R,R)-enantiomer of moxifloxacin up to 0.1 μg mL−1 for a 20 μL injection volume. The drug was subjected to stress conditions of hydrolysis, oxidation, photolysis and thermal degradation. There was no interference of degradants with the (R,R)-enantiomer in the developed method. The developed chiral RP-LC method was validated with respect to linearity, accuracy, precision and robustness. The percentage recovery for the (R,R)-enantiomer in bulk drug samples ranged from 98.1 to 104.4%. The test solution was found to be stable in the mobile phase for 48 h after preparation.


Column liquid chromatography Ligand-exchange liquid chromatography Forced degradation and validation Solution and mobile phase stability Moxifloxacin 



The authors wish to thank Professor D. N. Reddy, Principal, University College of Engineering, Osmania University for his constant encouragement and guidance.


  1. 1.
    Nightingale CH (2000) Pharmacotherapy 20:245–256. doi: 10.1592/phco. CrossRefGoogle Scholar
  2. 2.
    Radhakrishna T, Sreenivas Rao D, Vyas K, Om Reddy G (2000) J Pharm Biomed Anal 22:641–697. doi: 10.1016/S0731-7085(99)00302-7 CrossRefGoogle Scholar
  3. 3.
    Cruz LA, Hall R (2005) J Pharm Biomed Anal 38:8–13Google Scholar
  4. 4.
    Sahajwalla CG (2004) New drug development, vol 141. Marcel Dekker, Inc., New York, pp 421–426Google Scholar
  5. 5.
    Beesley TE, Scott RPW (1998) Chiral chromatography. Wiley, New York, pp 23–26Google Scholar
  6. 6.
    Lämmerhofer M, Gyllenhall O, Lindner W (2004) J Pharm Biomed Anal 35:259–266. doi: 10.1016/S0731-7085(03)00644-7 CrossRefGoogle Scholar
  7. 7.
    Bielejewska A, Duszezyk K, Zukoswski J (2005) Acta Chromatogr 15:183–191Google Scholar
  8. 8.
    Lu X, Liu P, Chen H, Qin F, Li F (2005) Biomed Chromatogr 19:703–708. doi: 10.1002/bmc.584 CrossRefGoogle Scholar
  9. 9.
    Davankov VA (1980) Resolution of racemates by ligand exchange chromatography. In: Advances in chromatography, vol 18. Marcel Dekker, NY, p 139Google Scholar
  10. 10.
    Davankov VA (1985) Chiral separations by HPLC. In: A. Krstulovic (ed) Applications to pharmaceutical compounds. Ellis Horwood, Chichester, p 175Google Scholar
  11. 11.
    Draft ICH Guidelines on Validation of Analytical Procedures (1995) Definitions and terminology, Federal Register. vol 60. IFPMA, Switzerland, p 11260Google Scholar
  12. 12.
    Validation of compendial methods (2007) The United States Pharmacopeia, 30th edn. USP30Google Scholar

Copyright information

© Vieweg+Teubner | GWV Fachverlage GmbH 2008

Authors and Affiliations

  • M. Ravikumar
    • 1
  • M. Satish Varma
    • 1
  • T. Satyanarayana Raju
    • 1
  • P. Suchitra
    • 2
  • P. Yadagiri Swamy
    • 1
  1. 1.Department of ChemistryUniversity College of Engineering, Osmania UniversityHyderabadIndia
  2. 2.Matrix Laboratories LimitedICICI Knowledge ParkHyderabadIndia

Personalised recommendations